RANDOMIZED CONTROL TRIAL: MYCOPHENOLATE MOFETIL IN PATIENTS W/ IGA NEPHROPATHY

随机对照试验：霉酚酸吗替酯治疗 IGA 肾病患者

• 批准号: 7375426
• 负责人: ROBERT J WYATT
• 金额: $ 0.43万
• 依托单位: UNIVERSITY OF TENNESSEE HEALTH SCI CTR
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375426
• 关键词: RANDOMIZED; CONTROL; TRIAL; MYCOPHENOLATE; MOFETIL

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This multicenter clinical trial tests the efficacy of Mycophenolate Mofetil in reducing proteinuria, which is usually equated with improvement in prognosis, in patients with IgA Nephropathy who are being maintained on a standard regimen of an angiotensin converting enzyme inhibitor and fish oil supplements.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。这项多中心临床试验测试了吗替麦考酚酯在减少蛋白尿方面的功效，蛋白尿通常等同于改善 IgA 肾病患者的预后，这些患者正在接受血管紧张素转换酶抑制剂和鱼油补充剂的标准治疗方案。